-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The phase 3 KEYNOTE-048 trial evaluated the overall efficacy of pembrolizumab in patients with recurrent or metastatic (R/M) head and neck sickle cell carcinoma (HNSCC) and according to PD-L1 combined positive score (CPS) Efficacy by group (CPS ≥ 1 point and CPS ≥ 20 points)
.
To further summarize the predictive value of PD-L1 expression level on patient prognosis, this study analyzed the efficacy of pembrolizumab in the subgroup of patients with PD-L1 CPS < 1 and CPS 1-19 in the KEYNOTE-048 trial
.
.
In this trial, patients with relapsed or metastatic HNSCC who had not received prior systemic therapy for relapsed or metastatic disease were randomized (1:1:1) to pembrolizumab, pembrolizumab-chemotherapy, or Cetuximab-chemotherapy group
.
The primary endpoints were overall survival (OS) and progression-free survival (PFS)
The primary endpoints were overall survival (OS) and progression-free survival (PFS)
128
Figure 1.
Pembrolizumab vs Cetuximab-Chemotherapy Overall Survival
- In the subgroup with PD-L1 CPS < 1, median OS was 7.
Figure 2.
Overall survival for pembrolizumab-chemotherapy vs cetuximab-chemotherapyPembrolizumab-chemotherapy vs cetuximab-chemotherapy: Median overall survival in the pembrolizumab-chemotherapy and cetuximab-chemotherapy groups in subgroups with PD-L1 CPS < 1 11.
3 and 10.In conclusion, as PD-L1 expression levels increased, the efficacy of pembrolizumab or pembrolizumab-chemotherapy in patients with recurrent or metastatic head and neck sickle cell carcinoma also increased
.
The results of the PD-L1 CPS 1-19 subgroup support the previously identified therapeutic benefit of pembrolizumab monotherapy and pembrolizumab-chemotherapy in patients with tumors with PD-L1 CPS ≥ 1
Efficacy of pembrolizumab or pembrolizumab-chemotherapy in patients with recurrent or metastatic head and neck sickle cell carcinoma increased with increased PD-L1 expression levelsOriginal source:
Original source:Burtness Barbara,Rischin Danny,Greil Richard et al.
Burtness Barbara,Rischin Danny,Greil Richard et al.
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
[J] .
J Clin Oncol , 2022, undefined: JCO2102198.
https://doi.
org/10.
1200/JCO.
21.
02198.
Leave a comment here
